Showing 2141-2150 of 5697 results for "".
- Sanofi’s Intravitreal Gene Therapy Earns FDA Fast Track Designation for Geographic Atrophyhttps://modernod.com/news/sanofis-intravitreal-gene-therapy-earns-fda-fast-track-designation-for-geographic-atrophy/2482888/The FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the developm
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMDhttps://modernod.com/news/alcon-to-acquire-lumithera-maker-of-photobiomodulation-device-for-the-treatment-of-dry-amd/2482873/In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD.
- Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.https://modernod.com/news/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc/2482871/Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid block
- Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trialhttps://modernod.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial/2482865/Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 p
- TFOS DEWS III Report Published with Updated Guidelines for Diagnosis and Management of DEDhttps://modernod.com/news/tfos-dews-iii-report-published-for-updated-guidelines-for-diagnosis-and-management-of-ded/2482849/The Tear Film and Ocular Surface Society (TFOS) has released the TFOS DEWS III report, its third set of reports exploring the diagnosis and management of dry eye disease. The findings of the TFOS DEWS III report were published in the
- ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapyhttps://modernod.com/news/vigeneron-rebrands-as-veongen-therapeutics-announces-fda-rare-pediatric-disease-designation-for-lead-gene-therapy/2482837/VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanc
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations
- SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patientshttps://modernod.com/news/spyglass-pharma-raises-75-million-series-d-funding-to-advance-its-long-term-drug-delivery-platform-for-glaucoma-patients/2482829/SpyGlass Pharma announced the closing of a $75 million Series D financing round to support the development of its drug delivery platform aimed at transforming the long-term treatment of glaucoma and other chronic eye diseases.
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen